BDXA

Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6

BDXA

Market cap $2.93B

Delisted

BDXA was delisted on the 30th of April, 2020.

Back to rankings

Healthcare Medical Instruments & Supplies

Financial journalist opinion

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings potential.

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

Becton Dickinson Q3 Beats Estimates On Medical Device Boom

As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company BDX are reporting robust financial performances that highlight their resilience and strategic adaptability. The company's stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.

Becton Dickinson Q3 Beats Estimates On Medical Device Boom

Becton Dickinson joins peer in raising annual profit forecast after results beat

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Becton Dickinson joins peer in raising annual profit forecast after results beat

Becton Dickinson gets its spinoff deal, but the stock is still falling

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.

Becton Dickinson gets its spinoff deal, but the stock is still falling

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027. Here's a breakdown of why the stock's structure looks weak under the lens of the Adhishthana Principles, our proprietary cyclical framework combining behavioral archetypes, timing structures, and quantitative signals.

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Becton Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Stock Of The Day – Bullish Capitulation In Becton, Dickinson?

Shares of Becton, Dickinson and Company BDX are coming back a little on Friday. This follows Thursday's more than 18% drop.

Stock Of The Day – Bullish Capitulation In Becton, Dickinson?

Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales

Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.

Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales

Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing

Becton, Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.

Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing

See News Rankings

Charts implemented using Lightweight Charts™